Converting from Warfarin to Apixaban (Eliquis) for Atrial Fibrillation
Stop warfarin and start apixaban when the INR drops below 2.0 1. This is the FDA-approved transition method and represents the safest, most straightforward approach to switching anticoagulants.
Transition Protocol
The FDA label for Eliquis provides explicit guidance 1:
- Discontinue warfarin completely
- Monitor INR until it falls below 2.0
- Start apixaban at the appropriate dose once INR < 2.0
- Do not overlap the two medications
This approach avoids the complexity and potential risks of bridging therapy while ensuring continuous anticoagulation coverage during the transition period.
Dosing Apixaban After the Switch
Most patients should receive apixaban 5 mg twice daily 1. However, reduce to 2.5 mg twice daily if the patient has at least two of the following characteristics 1:
- Age ≥80 years
- Body weight ≤60 kg
- Serum creatinine ≥1.5 mg/dL
This dose-reduction algorithm is critical—it requires meeting at least two criteria, not just one.
Why Switch from Warfarin to Apixaban?
Direct oral anticoagulants (DOACs) including apixaban are recommended over warfarin for eligible patients with non-valvular atrial fibrillation 2. The 2019 AHA/ACC/HRS guidelines give this a Class 2a, Level of Evidence A recommendation, representing the strongest current guidance.
The evidence supporting this preference is compelling:
Apixaban demonstrated superior efficacy and safety compared to warfarin in the ARISTOTLE trial, with significant reductions in stroke/systemic embolism (HR 0.79), major bleeding (HR 0.69), and all-cause mortality (HR 0.89) 3, 4
Real-world data confirms these benefits persist after switching: A 2025 Medicare study of 164,480 patients found that switching from warfarin to apixaban reduced the composite outcome of stroke, major bleeding, and death by 8% (RR 0.92) 5
Apixaban shows the best safety profile among DOACs: When compared head-to-head after warfarin switching, apixaban demonstrated lower rates of both stroke/SE and major bleeding versus dabigatran and rivaroxaban 6, 7
Critical Timing Consideration
Be aware of a temporary risk increase during the first 60 days after switching 5. The Medicare study showed an initial risk elevation immediately after transition, followed by risk attenuation beyond 60 days. This means:
- Schedule close follow-up within the first 2 months after switching
- Ensure the patient understands the importance of strict adherence during this vulnerable period
- Do not miss doses—apixaban's short half-life (12 hours) means missed doses create gaps in anticoagulation 8
Contraindications to Switching
Do not use apixaban (or any DOAC) in patients with 9, 2:
- Mechanical heart valves (Class III: Harm)
- Moderate-to-severe mitral stenosis (rheumatic)
- End-stage CKD on dialysis (insufficient evidence, though some European guidance differs 8)
For these patients, warfarin remains the anticoagulant of choice.
Renal Function Considerations
Apixaban has the lowest renal clearance (27%) among DOACs 8, making it particularly suitable for patients with moderate renal impairment (CrCl 30-50 mL/min). For severe renal impairment (CrCl 15-30 mL/min), the evidence is limited but apixaban may still be considered with the reduced dose 9, 8. Calculate creatinine clearance using the Cockcroft-Gault method and reassess renal function at least annually 9.
Drug Interactions
Reduce apixaban dose by 50% when coadministered with combined P-glycoprotein and strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir) 1. If the patient is already on 2.5 mg twice daily, avoid these combinations entirely 1.
Avoid P-glycoprotein inducers (phenytoin, carbamazepine, rifampin, St. John's wort) as they can reduce apixaban levels to subtherapeutic ranges 9.
Patient Education Points
- Take apixaban exactly twice daily, approximately 12 hours apart
- Do not double up if a dose is missed—take it as soon as remembered on the same day, then resume the regular schedule 1
- Unlike warfarin, no dietary restrictions or INR monitoring are required
- For patients unable to swallow tablets, apixaban can be crushed and mixed with water, apple juice, or applesauce 1
Common Pitfall to Avoid
Do not bridge with heparin or LMWH during the warfarin-to-apixaban transition. The FDA-approved method of waiting for INR < 2.0 eliminates the need for bridging and avoids the increased bleeding risk associated with overlapping anticoagulants 1. Bridging is only recommended for mechanical valve patients, which are not candidates for apixaban anyway 9.